A benefit–risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy

References

• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62:335-46
   PubMed Web of Science ®Google Scholar
• Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing–remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011;32:83-8
   PubMed Web of Science ®Google Scholar
• Svenningsson A, Falk E, Celius EG, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One 2013;8:e58643
   PubMed Web of Science ®Google Scholar
• Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:742-50
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Edan G, Giovannoni G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
   PubMed Web of Science ®Google Scholar
• Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2004;(1):CD004678
   Google Scholar
• Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522-5
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Natalizumab (Tysabri) for the treatment of adults with highly active relapsing remitting multiple sclerosis. 2007
   Google Scholar
• National Institute for Health and Clinical Excellence. NICE technology appraisal guidance: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis. Available at: http://guidance.nice.org.uk/TA/Wave10/14 [Accessed Nov 2011]
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. England and Wales interim life tables. Available at: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-61850 [Accessed Feb 2012]
   Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
   PubMedGoogle Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-28
   PubMed Web of Science ®Google Scholar
• Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand 1982;65:248-66
   PubMed Web of Science ®Google Scholar
• Hutchison M, Fox RJ, Havrdova E, et al. Systematic literature review and mixed treatment comparison of BG-12 (dimethyl fumarate) and disease modifying therapies for relapsing–remitting multiple sclerosis. Poster at the 65th Annual Meeting of the American Academy of Neurology, March 2013, San Diego, CA, USA
   Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• British Neurology Society. Revised (2009) Association of British Neurologists’ guidelines for prescribing in multiple sclerosis. 2009
   Google Scholar
• Herndon RM, Rudick RA, Munschauer FE III, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005;11:409-19
   PubMed Web of Science ®Google Scholar
• Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996;15:209-31
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
   PubMed Web of Science ®Google Scholar
• Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005;46:4016-23
   PubMed Web of Science ®Google Scholar
• Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169-89
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. Fingolimod for the treatment of relapsing–remitting multiple sclerosis in adults: NICE Single Technology Appraisal. 2011
   Google Scholar
• van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454-67
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Underwood A, Jit M, et al. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One 2011;6:e17030
   PubMed Web of Science ®Google Scholar